Foresite Capital

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Myome is a company focused on gene analytics technology that aims to enhance understanding of how DNA influences health and well-being. By utilizing genome sequencing, Myome provides insights into a range of common and rare diseases, including coronary heart disease. This technology allows for the estimation of risks associated with various multifactorial medical conditions, empowering families to take proactive measures to reduce the transmission of genetic diseases across generations. The data generated by Myome is designed to be secure, portable, and reusable throughout an individual's life, facilitating ongoing health management.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

Developer of transformative biotech company intended to create, annotate and biologically understand the world's most rigorous and extensive library of microproteins and produce entirely new, novel therapeutics. The company's technology identify novel, protein coding sequences hidden within the human genome, these small proteins mediate rich and diverse human biology, thereby harnessing the therapeutic potential of a novel class of human peptides.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Sestina Bio, LLC is a biotechnology company founded in 2020 and based in Delaware. The company focuses on developing a synthetic biology platform that engineers yeast and bacteria to produce chemicals and pharmaceuticals. Sestina Bio integrates innovative advances in synthetic biology, data sciences, and bio-analytical systems to create solutions addressing significant global challenges, such as sustainable food production, clothing, and health for an expanding population. Their offerings include tools for genome editing, single-cell biology, and machine learning, which enhance researchers' capabilities to engineer and exploit new biological functions.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

10x Genomics is a life science technology company based in Pleasanton, California, that specializes in developing instruments, consumables, and software for the analysis of biological systems. Founded in 2012, the company offers a range of products, including Chromium instruments, microfluidic chips, slides, reagents, and various consumable products. Its innovative single cell solutions enable researchers to assess gene expression, immune profiling, epigenetics, and cellular heterogeneity at an individual cell level. The Visium spatial gene expression solution allows for the analysis of gene expression patterns across tissue samples, providing valuable insights into biological processes. 10x Genomics serves a diverse client base, including academic institutions, government organizations, and biopharmaceutical companies across multiple regions, including North America, Europe, and Asia. The company generates the majority of its revenue from consumables, underscoring its focus on providing essential tools for genomic research.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

AveXis, now known as Novartis Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies aimed at treating rare and life-threatening neurological genetic disorders. Acquired by Novartis in 2018, the company specializes in motor neuron cell-targeted gene replacement therapies for conditions such as spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. By addressing these severe diseases, which often result in progressive muscle weakness, paralysis, and death, AveXis plays a crucial role in enhancing treatment options for affected patients and their families.

Intellia Therapeutics, Inc. is a genome editing company headquartered in Cambridge, Massachusetts, specializing in the development of therapeutics using the CRISPR/Cas9 technology. This innovative platform allows for precise alterations of genomic DNA, enabling the company to pursue treatments for a range of severe and life-threatening diseases. Intellia's pipeline includes both in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as ex vivo programs focused on engineered cell therapies for oncological and autoimmune disorders. The company is also exploring treatments for conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Intellia has established collaborations with several organizations, enhancing its research and development capabilities. Founded in 2014, Intellia holds a significant intellectual property portfolio related to the therapeutic applications of CRISPR/Cas9, aiming to address high unmet medical needs through its advanced gene-editing approaches.

Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.

Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

10x Genomics is a life science technology company based in Pleasanton, California, that specializes in developing instruments, consumables, and software for the analysis of biological systems. Founded in 2012, the company offers a range of products, including Chromium instruments, microfluidic chips, slides, reagents, and various consumable products. Its innovative single cell solutions enable researchers to assess gene expression, immune profiling, epigenetics, and cellular heterogeneity at an individual cell level. The Visium spatial gene expression solution allows for the analysis of gene expression patterns across tissue samples, providing valuable insights into biological processes. 10x Genomics serves a diverse client base, including academic institutions, government organizations, and biopharmaceutical companies across multiple regions, including North America, Europe, and Asia. The company generates the majority of its revenue from consumables, underscoring its focus on providing essential tools for genomic research.

Sequenta is a biotech company focused on developing clinical diagnostics that leverage a novel platform for assessing immune system status. Founded in 2008 by entrepreneurs with prior experience in the biotech sector, Sequenta aims to create innovative methods for measuring the immune cell receptor genes, which represent the most variable segment of the human genome. The advancements in DNA sequencing technology have enabled the company to devise unique approaches that can inform numerous clinical decisions through a single, powerful assay. By tapping into the genetic diversity of immune cell receptors, Sequenta addresses critical health conditions and disease management, positioning itself as a significant player in the field of clinical diagnostics.